Loading…
Loading…
Avivagen (OTCMKTS:VIVXF - Get Free Report) and High Tide (NASDAQ: HITI - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Analyst Ratings This is a summary of current ratings
Stryker (NYSE: SYK - Get Free Report) and Avivagen (OTCMKTS:VIVXF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Institutional and Insider Ownership 77.1% of Stryker shares are held
Ottawa, Ontario--(Newsfile Corp. - April 24, 2024) - Avivagen Inc. (TSXV: VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance feed intake and support immune function, thereby supporting general health and performance, announced today that is has made a voluntary assignment in bankruptcy for the benefit of its creditors pursuant to section 49 of the Bankruptcy and Insolvency Act (Canada) ("BIA"). BDO Canada Limited has consented to act as Licensed Insolvency Trustee and will administer the estate and realize on the Company's assets in accordance with the BIA.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce a 500kg order for OxC-beta™. The purchase follows a 500kg order in July from the same customer, based in Taiwan, for use within the sow ma.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2023. Third Quarter July 31, 2023, Financial Results The Company's unaudited Financial Statements for the t.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announces several corporate updates, relating to the allowances of patents, a waiver of an interest payment on its senior secured debentures and the contin.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV.VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce two orders for OxC-beta™. One order, for 500kgs, is with a new customer for use within the sow market, while the second order, for 600kgs,.
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common sha
No recent filings indexed.